• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Avid Bioservices Inc.

    12/23/24 4:24:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDMO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001817685
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    AVID BIOSERVICES INC..
    SEC File Number
    001-32839
    Address of Issuer
    2642 Michelle Drive
    Tustin,
    CALIFORNIA
    92780
    Phone
    (714) 508-6000
    Name of Person for Whose Account the Securities are To Be Sold
    NICHOLAS GREEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1000001227940.006414250912/23/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked172901/09/2023Services Rendered
    Common04/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked263304/09/2023Services Rendered
    Common04/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked416904/09/2023Services Rendered
    Common06/28/2023Performance Stock UnitsCDMOCheckbox not checked2222306/28/2023Services Rendered
    Common06/28/2023Performance Stock UnitsCDMOCheckbox not checked1431306/28/2023Services Rendered
    Common06/30/2023Shares Purchased through Employee Stock Purchase PlanCDMOCheckbox not checked92706/30/2023Cash
    Common07/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked265807/09/2023Services Rendered
    Common07/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked421107/09/2023Services Rendered
    Common07/30/2023Restricted stock vesting under a registered planCDMOCheckbox not checked1798107/30/2023Services Rendered
    Common10/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked557310/09/2023Services Rendered
    Common10/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked882610/09/2023Services Rendered
    Common10/09/2023Restricted stock vesting under a registered planCDMOCheckbox not checked847710/09/2023Services Rendered
    Common12/29/2023Shares Purchased through Employee Stock Purchase PlanCDMOCheckbox not checked89212/29/2023Cash
    Common01/09/2024Restricted stock vesting under a registered planCDMOCheckbox not checked538801/09/2024Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024263532442.65
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/20244505540.49
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/202420079247216.66
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024263432430.33
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/202418442227061.59
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024267332910.51
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024423452129.01
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/202481510034.44
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024364644890.28
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/202492411376.47
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024105312964.75
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/202411799145271.65
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024278734314.10
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/20244705786.73
    NICHOLAS GREEN
    2642 Michelle Drive
    Tustin, � CA � 92780
    Common12/20/2024235929044.48

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/23/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Nicholas Green

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CDMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDMO

    DatePrice TargetRatingAnalyst
    9/28/2023Mkt Perform
    William Blair
    3/14/2023$20.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/9/2022$31.00 → $28.00Overweight
    Stephens & Co.
    12/8/2021$29.00 → $35.00Buy
    Craig-Hallum
    12/8/2021$27.00 → $32.00Outperform
    RBC Capital
    12/8/2021Overweight → Sector Weight
    Keybanc
    6/30/2021$21.00 → $29.00Buy
    Craig-Hallum
    6/30/2021$21.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    1/10/24 7:56:02 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    12/18/23 7:31:12 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    9/22/23 12:51:46 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    SEC Filings

    View All

    SEC Form 15-12G filed by Avid Bioservices Inc.

    15-12G - Avid Bioservices, Inc. (0000704562) (Filer)

    2/18/25 6:07:47 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:38 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:36 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Avid Bioservices

    William Blair initiated coverage of Avid Bioservices with a rating of Mkt Perform

    9/28/23 8:08:44 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Avid Bioservices from Sector Weight to Overweight and set a new price target of $20.00

    3/14/23 7:17:41 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

    Stephens & Co. reiterated coverage of Avid Bioservices with a rating of Overweight and set a new price target of $28.00 from $31.00 previously

    3/9/22 6:57:34 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:25 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:10 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:39:57 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

    TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers. The reimagined Avid website captures the company's elevated brand throu

    2/10/25 8:05:59 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

    TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the "Notice") to holders of its 7.00% Convertible Senior Notes due 2029 (the "Notes"), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the "Indenture"), by and between the Company and U.S. Bank Trust Company, National Association ("U.S. Bank"), as trustee, governing the Notes that, in connection with the closing of the transa

    2/5/25 10:45:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

    Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ("Ampersand"), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices

    2/5/25 9:55:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Financials

    Live finance-specific insights

    View All

    Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024

    TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," stated Nick Green, president and CEO of Avid Bioservices. "We are pleased to reach the separately announced agre

    12/10/24 4:05:23 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

    -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:

    9/9/24 4:05:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

    TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please

    9/3/24 4:05:20 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Leadership Updates

    Live Leadership Updates

    View All

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Avid Bioservices Appoints Oksana Lukash as Vice President, People

    TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year

    11/16/22 8:05:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/14/24 7:53:01 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/12/24 4:15:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care